Alzheimer's Disease Clinical Trials

This is a study to test the safety and tolerability of the research study drug, suvorexant and test the effects of suvorexant compared to placebo in improving insomnia in subjects with mild to moderate Alzheimer’s disease.

This study tests whether two investigational drugs called CAD106 and CNP520, administered separately, can delay and slow the progression of clinical symptoms associated with Alzheimer's Disease in participants at risk of developing clinical symptoms based on their age and genotype.   Other Details: https://clinicaltrials.gov/ct2/show/NCT02565511

Evaluate the efficacy of Lanabecestat in mild Alzheimer's Disease dementia   Other Details:  https://clinicaltrials.gov/ct2/show/study/NCT02783573

The primary objective is to evaluate the effects of administration of neflamapimod (VX-745) for 24-weeks on immediate and delayed recall aspects of episodic memory, as assessed by the Hopkins Verbal Learning Test – Revised (HVLT-R) in subjects with mild Alzheimer’s disease (AD).

The purpose of this study is to evaluate whether the investigational medication, JNJ-54861911, slows cognitive decline compared with placebo (inactive treatment) in individuals with generally normal memory and thinking ability but who are at risk for developing Alzheimer's dementia.  Study qualification and whether or not a potential study participant is ...

The primary objective of this study is to determine whether treatment with an oral investigational drug can slow cognitive decline compared with placebo treatment in individuals who are asymptomatic but at high risk for Alzheimer's disease. Asymptomatic means that the individual is not currently experiencing any symptoms of memory loss ...

Study Description: CREAD2 is a Phase 3 study investigating the effect of an investigational drug in the form of an infusion on Alzheimer's disease progression in individuals with prodromal to mild Alzheimer's disease. The study drug, crenezumab, is a monoclonal antibody that targets amyloid-beta proteins in the brain. The study ...

The purpose of this study is to find out if a study drug is safe and effective in the treatment of agitation caused by dementia. Volunteers will receive compensations up to $80.00 per completed visit, for their overall participation in this study to cover their time and travel. Volunteers will ...

The MISSION-AD study is investigating the efficacy and safety of an investigational drug on symptoms of cognitive decline in individuals with mild cognitive impairment or early Alzheimer's disease. The study drug is a tablet which is taken by mouth once per day. The study will last approximately two years. Eligibility ...

This is a study for elderly patients (>= 55 years of age) who meet the NINCDS-ADRDA criteria for Alzheimer's Disease. Patients screened at visit 1 who will meet all of the inclusion criteria, will be enrolled in the study and receive study therapy. Qualified volunteers will receive compensation up to ...